{"id":1583,"date":"2019-05-28T08:00:00","date_gmt":"2019-05-28T08:00:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-oncopeptides-kommer-att-presentera-vid-jefferies-healthcare-conference-i-new-york-den-7-juni-klockan-11-30am-lokal-tid\/"},"modified":"2026-02-23T13:18:30","modified_gmt":"2026-02-23T13:18:30","slug":"oncopeptides-ab-oncopeptides-kommer-att-presentera-vid-jefferies-healthcare-conference-i-new-york-den-7-juni-klockan-11-30am-lokal-tid","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-kommer-att-presentera-vid-jefferies-healthcare-conference-i-new-york-den-7-juni-klockan-11-30am-lokal-tid\/","title":{"rendered":"Oncopeptides AB: Oncopeptides kommer att presentera vid Jefferies Healthcare Conference i New York den 7 juni klockan 11.30am lokal tid"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">Stockholm &#8211; 28 maj 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) meddelar idag att de kommer att delta vid Jefferies &aring;rliga Healthcare Conference i New York mellan den 4-7 juni och ha en plenumpresentation den 7 juni 11.30am lokal tid (EST).<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">Presentationen kommer att webcastas och kommer att finnas tillg&auml;nglig under:<br \/>www.oncopeptides.com \/ Investerare &amp; Media \/ Presentationer \/ Jefferies 2019 Global Healthcare Conference&nbsp;<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information, kontakta:&nbsp;<br \/>Rein Piir, Head of Investor Relations f&ouml;r Oncopeptides<br \/>E-post: rein.piir@oncopeptides.com<\/p>\n<p class=\"mfn-wp-retain\">Information l&auml;mnades f&ouml;r offentligg&ouml;rande den 28 maj 2019 kl. 10.00 (CET).<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<br \/>Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag som utvecklar l&auml;kemedel f&ouml;r behandling av cancer. Bolaget fokuserar p&aring; utvecklingen av produktkandidaten melflufen, en lipofil peptidl&auml;nkad alkylerare, tillh&ouml;rande en ny l&auml;kemedelsklass kallad Peptidase Enhanced Cytotoxics (PEnC). Melflufen utvecklas som en ny behandling av den hematologiska cancersjukdomen multipelt myelom och testas f&ouml;r n&auml;rvarande i en global registreringsgrundade klinisk fas 3-studie kallad OCEAN, en fas 2-studie kallad HORIZON samt i tv&aring; ytterligare p&aring;g&aring;ende kliniska pr&ouml;vningar. Oncopeptides har huvudkontor i Stockholm och &auml;r noterat i Mid Cap-segmentet p&aring; Nasdaq Stockholm med kortnamn ONCO.<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information bes&ouml;k www.oncopeptides.com.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2826426%2F1052858.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2826426%2F1052858.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Stockholm &#8211; 28 maj 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) meddelar idag att de kommer att delta vid Jefferies &aring;rliga Healthcare Conference i New York mellan den 4-7 juni och ha en plenumpresentation den 7 juni 11.30am lokal tid (EST). Presentationen kommer att webcastas och kommer att finnas tillg&auml;nglig under:www.oncopeptides.com \/ Investerare &amp; Media [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[174,171,180],"class_list":["post-1583","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1583"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1583"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}